Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons
Husa, P.; Husova, L.
Bratislavske Lekarske Listy 102(5): 248-252
2001
ISSN/ISBN: 0006-9248 PMID: 11725377 Document Number: 526663
Hepatitis C is a major health problem. In recent years, the treatment of choice is alpha-interferon in combination with ribavirin. For patients with failure of this treatment the therapy with consensus or pegylated interferons, in monotherapy or in combination with ribavirin, present other possibilities. We can expect the development more potent antiviral drugs or immune modulators for patients, which are primary resistant to alpha-interferon. (Tab. 3, Ref. 31)
Document emailed within 1 workday
Related Documents
Ali, S.; Nazir, G.; Khan, S.A.; Iram, S.; Fatima, F. 2010: Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients Journal of Ayub Medical College Abbottabad: Jamc 22(4): 127-130Ferenci, P. 2006: Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future Minerva Gastroenterologica e Dietologica 52(2): 157-174
Elefsiniotis, I.S.; Fotos, N.V.; Pantazis, K.D.; Papadeli, D.; Mavrogiannis, C. 2007: Celiac disease in chronic hepatitis C patients under pegylated-interferon plus ribavirin treatment. Preliminary results of a prospective single center study Hepato-Gastroenterology 54(75): 2 PPreceding Table of Contents
Słuzewski, W.; Kowala-Piaskowska, A.; Wysocki, J.; Figlerowicz, M.; Gorczyca, A.; Halota, W.; Jóźwiak, H.; Mizerski, J.; Mozer-Lisewska, I.; Pawłowska, M.łg.; Rokitka, M.; Strawińska, E.; Szamotulska, K. 2012: Treatment of chronic hepatitis C in children with pegylated interferon α2a and ribavirin--a multi-center study Acta Poloniae Pharmaceutica 69(2): 319-326
Urbánek, P.; Subhanová, I.; Janousová, E.; Dusek, L.; Marecek, Z.; Brůha, R.; Petrtýl, J.; Brodanová, M. 2009: Efficacy of combination treatment with pegylated interferon plus ribavirin in patients chronically infected with HCV Vnitrni Lekarstvi 55(5): 474-479
Srivastava, S.; Bertagnolli, M.; Lewis, J.H. 2005: Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic Journal of the National Medical Association 97(12): 1703-1707
Sarin, S.K.; Kumar, M.; Hissar, S.; Sharma, B.C. 2006: Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment Hepatobiliary and Pancreatic Diseases International: Hbpd Int 5(3): 374-380
Pawłowska, M.łg.; Halota, W. 2006: Pegylated interferon alpha in the treatment of chronic hepatitis B in HBe negative patients Przeglad Epidemiologiczny 60(1): 105-108
Mozer-Lisewska, I.; Dworacki, G.; Kaczmarek, E.; Słuzewski, W.; Kowala-Piaskowska, A.; Figlerowicz, M.; Kaczmarek, M.; Zeromski, J. 2005: Alterations within white blood cell subsets in children with chronic viral hepatitis C before treatment with pegylated interferon and ribavirin Przeglad Epidemiologiczny 59(2): 483-489
Abutidze, A.; Bolokadze, N.; Chkhartishvili, N.; Sharvadze, L.; Tsertsvadze, T. 2016: Incidence of Tuberculosis among Hiv/Hcv Co-Infected Patients Receiving Hepatitis C Treatment with Pegylated Interferon and Ribavirin in Georgia Georgian Medical News 252: 10-15
Chu, C-Jen.; Wang, Y-Jen.; Hwang, S-Jang.; Lu, R-Hwa.; Chang, F-Young.; Chang, C-Yu.; Yang, Y-Chun.; Lee, S-Dong. 2007: Kinetics of hepatitis C virus RNA load during pegylated interferon plus ribavirin therapy in Treatment-naive Chinese patients Hepato-Gastroenterology 54(75): 866-870
Yu, J.; Liu, B.-w.; Lan, L.; Yuan, Y.; Zhang, H.; Jia, C.-h. 2010: Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 24(5): 373-375
Juszczyk, J.; Baka-Cwierz, B.; Beniowski, M.; Berak, H.; Bolewska, B.; Boroń-Kaczmarska, A.; Cianciara, J.; Cieśla, A.; Dziambor, A.; Gasiorowski, J.; Gietka, A.; Gliwińska, E.; Gładysz, A.; Gonciarz, Z.; Halota, W.; Horban, A.; Inglot, Młgorzata.; Janas-Skulina, U.; Janczewska-Kazek, E.; Jaskowska, J.; Jurczyk, K.; Knysz, B.; Kryczka, Wław.; Kuydowicz, J.; Lakomy, E.A.; Logiewa-Bazger, B.; Lyczak, A.; Mach, T.; Mazur, Włodzimierz.; Michalska, Z.; Modrzewska, R.; Nazzal, K.; Pabjan, Pł.; Piekarska, A.; Piszko, Pł.; Sikorska, K.; Szamotulska, K.; Sliwińska, M 2005: Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report) Przeglad Epidemiologiczny 59(3): 651-660
Bolukbas, C.; Bolukbas, F.F.; Kebdir, T.; Canayaz, L.; Dalay, A.R.; Kilic, G.; Ovunc, O. 2005: Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature Acta Gastro-Enterologica Belgica 68(4): 432-434
Khokhar, N. 2002: Effectiveness of 48 weeks Interferon alfa-2b in combination with ribavirin as initial treatment of chronic hepatitis Journal of Ayub Medical College Abbottabad: Jamc 14(3): 5-8
Vashakidze, E.; Imnadze, T. 2017: Combined Antiviral Treatment of Hepatitis C Virus Infection with Pegylated Interferon (Peg-Ifn) Α-2a (Pegferon) and Ribavirin (Copegus) in Inmates Georgian Medical News 264: 86-90
Mukherjee, S.; Lyden, E. 2006: Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series Hepato-Gastroenterology 53(70): 561-565
Jensen, S.L.; Holmes, R. 2003: Rosacea fulminans associated with pegylated interferon alpha-2B and ribavirin therapy Journal of Drugs in Dermatology: Jdd 2(5): 554-556
Durante-Mangoni, E.; Iardino, P.; Utili, R.; Adinolfi, L.E.; Ruggiero, G. 2006: Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts Antiviral Therapy 11(5): 637-640
Arase, Y. 2011: Combination therapy of PEG-interferon and ribavirin for chronic hepatitis C in Japan Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 4): 191-195